BR0111182A - Peptìdeos neuroprotetores - Google Patents
Peptìdeos neuroprotetoresInfo
- Publication number
- BR0111182A BR0111182A BR0111182-5A BR0111182A BR0111182A BR 0111182 A BR0111182 A BR 0111182A BR 0111182 A BR0111182 A BR 0111182A BR 0111182 A BR0111182 A BR 0111182A
- Authority
- BR
- Brazil
- Prior art keywords
- erythropoietin
- peptides
- activity
- human erythropoietin
- therapeutic
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 102000044890 human EPO Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000001067 neuroprotector Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20765400P | 2000-05-26 | 2000-05-26 | |
| PCT/US2001/016654 WO2001091780A1 (en) | 2000-05-26 | 2001-05-23 | Neuroprotective peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0111182A true BR0111182A (pt) | 2004-02-25 |
Family
ID=22771463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0111182-5A BR0111182A (pt) | 2000-05-26 | 2001-05-23 | Peptìdeos neuroprotetores |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1296702A4 (enExample) |
| JP (1) | JP2003534384A (enExample) |
| CN (1) | CN1318084C (enExample) |
| AU (2) | AU7490401A (enExample) |
| BR (1) | BR0111182A (enExample) |
| CA (1) | CA2410453A1 (enExample) |
| IL (1) | IL153079A0 (enExample) |
| MX (1) | MXPA02011727A (enExample) |
| NZ (1) | NZ522924A (enExample) |
| WO (1) | WO2001091780A1 (enExample) |
| ZA (1) | ZA200210304B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE296350T1 (de) | 1999-06-14 | 2005-06-15 | Genentech Inc | Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage |
| US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| EP1625156B1 (en) * | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| EP1626983B8 (en) | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| AU2004238870B8 (en) | 2003-05-12 | 2010-04-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| EP1848461A2 (en) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| EP2275142A3 (en) | 2006-06-30 | 2011-05-11 | Andre Koltermann | Conjugates for immunotherapy of cancer |
| EP2118127A4 (en) | 2007-01-31 | 2010-12-01 | Affymax Inc | NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES |
| EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
| SG10201604530SA (en) * | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US8426402B2 (en) | 2009-02-05 | 2013-04-23 | Immunogen, Inc. | Benzodiazepine derivatives |
| RU2410392C2 (ru) | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| IL279304B (en) * | 2011-02-15 | 2022-07-01 | Immunogen Inc | Method for producing an indolinobenzodiazepine |
| KR20160052537A (ko) * | 2013-07-17 | 2016-05-12 | 아라임 파마슈티칼즈, 인크. | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| CN105017406B (zh) * | 2014-04-21 | 2020-10-09 | 上海市第一人民医院 | 一类新的具有神经保护功能的多肽 |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
| TW202024117A (zh) | 2018-09-14 | 2020-07-01 | 日商Ｅｐｏ醫藥股份有限公司 | 抗紅血球生成素受體胜肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
-
2001
- 2001-05-23 IL IL15307901A patent/IL153079A0/xx unknown
- 2001-05-23 NZ NZ52292401A patent/NZ522924A/xx not_active IP Right Cessation
- 2001-05-23 BR BR0111182-5A patent/BR0111182A/pt not_active Application Discontinuation
- 2001-05-23 MX MXPA02011727A patent/MXPA02011727A/es unknown
- 2001-05-23 AU AU7490401A patent/AU7490401A/xx active Pending
- 2001-05-23 AU AU2001274904A patent/AU2001274904B2/en not_active Ceased
- 2001-05-23 WO PCT/US2001/016654 patent/WO2001091780A1/en not_active Ceased
- 2001-05-23 JP JP2001587795A patent/JP2003534384A/ja active Pending
- 2001-05-23 EP EP01941562A patent/EP1296702A4/en not_active Withdrawn
- 2001-05-23 CN CNB018131794A patent/CN1318084C/zh not_active Expired - Fee Related
- 2001-05-23 CA CA002410453A patent/CA2410453A1/en not_active Abandoned
-
2002
- 2002-12-19 ZA ZA200210304A patent/ZA200210304B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1296702A1 (en) | 2003-04-02 |
| CA2410453A1 (en) | 2001-12-06 |
| CN1452492A (zh) | 2003-10-29 |
| HK1058484A1 (zh) | 2004-05-21 |
| WO2001091780A1 (en) | 2001-12-06 |
| JP2003534384A (ja) | 2003-11-18 |
| MXPA02011727A (es) | 2003-10-24 |
| IL153079A0 (en) | 2003-06-24 |
| AU2001274904B2 (en) | 2006-08-31 |
| EP1296702A4 (en) | 2005-05-11 |
| NZ522924A (en) | 2004-12-24 |
| CN1318084C (zh) | 2007-05-30 |
| AU7490401A (en) | 2001-12-11 |
| ZA200210304B (en) | 2004-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0111182A (pt) | Peptìdeos neuroprotetores | |
| ATE389724T1 (de) | Menschliche dnase i hyperaktive varianten | |
| ATE446365T1 (de) | Menschliches fgf-21 gen und genexpressionsprodukte | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| CY1107533T1 (el) | Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2 | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| DK1151009T3 (da) | Antimikrobielt/endotoksin-neutraliserende polypeptid | |
| PT698108E (pt) | Vectores adenovirais de origem animal e utilizacao em terapia genica | |
| ATE467425T1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
| ATE386808T1 (de) | Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel | |
| BR9714677A (pt) | "enantiÈmeros 3-piridila e seu uso como analgésicos" | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
| WO2002029087A3 (en) | Use of lymphangiogenic agents to treat lymphatic disorders | |
| DE69835680D1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| SE0102147D0 (sv) | New methods | |
| IL121272A (en) | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia | |
| BR0112131A (pt) | Composições farmacêuticas e métodos para uso | |
| DE60035192D1 (de) | Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung | |
| BR0210578A (pt) | Remédios para doenças eosinofìlicas | |
| GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
| YU60199A (sh) | Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji | |
| DE69314586D1 (de) | Arzneimittelzusammensetzung enthaltend TCF-II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Free format text: JOHNSON & JOHNSON (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |